Review of biologics in allergic contact dermatitis |
| |
| Authors: | Jushya Bhatia Ankur Sarin Uwe Wollina Torello Lotti Alexander A. Navarini Simon M. Mueller Stephan Grabbe Joachim Saloga Ghasem R. Rokni Mohamad Goldust |
| |
| Affiliation: | 1. Department of Dermatology, Sarin Skin Solutions, New Delhi, India;2. Department of Dermatology and Allergology, Städtisches Klinikum Dresden, Academic Teaching Hospital of the Technical University of Dresden, Dresden, Germany;3. Department of Dermatology, University of Studies Guglielmo Marconi, Rome, Italy;4. Department of Dermatology & Allergy, University Hospital of Basel, Basel, Switzerland;5. Department of Dermatology, University Hospital Basel, Basel, Switzerland;6. Department of Dermatology, University Medical Center Mainz, Mainz, Germany;7. Associate Professor of Dermatology, Department of Dermatology, Mazandaran University of Medical Sciences, Sari, Iran |
| |
| Abstract: | The resistant and recalcitrant nature of severe allergic contact dermatitis (ACD) makes its management challenging. With advances in the understanding of the cellular and molecular pathogenesis of ACD, newer therapeutic targets are becoming apparent. In particular, the use of biologics has gained momentum, given the specificity of their action. This article aims to review the presently available data on the use of biologics in ACD. English-language–based literature available on the use of biological therapy was thoroughly probed in the following databases as on October 14, 2019: PubMed, Google Scholar, The Cochrane library, Embase, Scopus, and EBSCO. The following keywords were used: “contact dermatitis”, “allergens”, “delayed-type hypersensitivity reaction”, “biologics”, “biological therapy”, “monoclonal antibodies”, “patch testing”, “TNF-α inhibitors”, “infliximab”, “adalimumab”, “etanercept”, “dupilumab”, “omalizumab”, “secukinumab”, “ustekinumab”, “rituximab”. |
| |
| Keywords: | allergic contact dermatitis biologics review treatment |
|
|
